Sunesis Pharmaceuticals, Inc. (SNSS) Stock: Here’s What’s Happening


Sunesis Pharmaceuticals, Inc. (SNSS) is making a move up in the market today. The company, one that is focused on the biotechnology sector, is presently priced at $0.92 after a move up of 5.75% so far today. In terms of biotechnology stocks, there are several aspects that have the ability to cause price movement in the market. News tends to be one of the biggest reasons for the movement. Here are the recent headlines surrounding SNSS:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Mar-15-19 08:21AM Will Sunesis Pharmaceuticals Continue to Surge Higher?
Mar-14-19 11:32AM Edited Transcript of SNSS earnings conference call or presentation 7-Mar-19 9:30pm GMT
Mar-07-19 04:01PM Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2018 Financial Results and Recent Highlights
Mar-04-19 07:00AM Sunesis Pharmaceuticals to Participate in Upcoming Investor Conferences
Mar-01-19 10:17AM Puma Biotech (PBYI) Q4 Loss Narrows, Nerlynx Pulls Stock Up

However, any time investors are making a decision to invest, investors should take a look at far more than news, this is especially the case in the generally speculative biotechnology space. Here’s what’s going on with Sunesis Pharmaceuticals, Inc..

Recent Trends From SNSS

Although a single session gain, like what we’re seeing from Sunesis Pharmaceuticals, Inc. might cause excitement in some investors, a single session move by itself should not be the basis of a decision to, or not to, invest in a company. It’s generally a good idea to look into trends experienced by the stock beyond a single trading day. When it comes to SNSS, here are the returns on investment that we’ve seen:

  • Past 5 Sessions – Over the past seven days, SNSS has produced a change in price that amounts to 43.64%.
  • Past 30 Days – The monthly performance from Sunesis Pharmaceuticals, Inc. has been 73.58%.
  • Quarterly – Throughout the last three months, the stock has produced a return that works out to 130.00%
  • Past Six Months – Throughout the previous six months, we have seen a performance that works out to -54.23% from the company.
  • YTD – Since the the last trading session of last year SNSS has resulted in a ROI of 121.31%.
  • Full Year – Lastly, over the past full year, investors have seen performance in the amount of -74.30% out of SNSS. Throughout this period of time, the stock has traded at a high of -75.68% and a low price of 360.00%.

Ratios Of Note

Digging into various key ratios associated with a stock can provide traders an understanding of how dangerous and/or potentially profitable a an investment option may be. Here are a few of the key ratios to think about when looking at SNSS.

Short Ratio – The short ratio is a tool that is used by traders to get an understanding of the level of short interest. As the ratio heads up, it shows that more investors are expecting that the price of the stock is headed for declines. Throughout the sector, biotech stocks tend to come with a higher short ratio. However, we also see quite a few short squeezes in the industry. Nonetheless, as it relates to Sunesis Pharmaceuticals, Inc., it’s short ratio amounts to 0.37.

Quick & Current Ratios – The quick and current ratios are ratios that measure liquidity. Basically, they measure If a company is able to cover its debts when they mature with only current assets or quick assets. In the biotech sector, several companies are reliant on continued support from investors, the quick and current ratios can be damning. Nonetheless, quite a few good picks in the biotechnology industry come with great current and quick ratios. When it comes to SNSS, the quick and current ratios total up to 1.30 and 1.30 respectively.  

Book To Share Value – The book to share value compares the the share price to the current book value of assets that are owned by the company. as it relates to Sunesis Pharmaceuticals, Inc., the book to share value ratio comes in at -0.45.

Cash To Share Value – Finally, the cash to share value comparison compares the total cash on hand to the price of the company’s stock. Several clinical stage biotech companies have a hard time keeping cash on hand. So, if you’re interested in a stock in the biotech sector, this is an important ratio to look into. In the case of SNSS, the cash to share value ratio comes to 0.21.

Analyst Opinions Of Sunesis Pharmaceuticals, Inc.

While it’s not a smart idea to unknowingly follow the opinions of analysts, it is a smart idea to consider their thoughts to validate your own due diligence when it comes to making investment decisions in the biotech space. Below you’ll find|Here are} the most recent moves that we have seen from analysts with regard to SNSS.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Dec-20-18 Initiated H.C. Wainwright Neutral
Dec-11-17 Upgrade Wells Fargo Market Perform → Outperform
Dec-05-17 Downgrade Wells Fargo Outperform → Market Perform
Jul-29-16 Upgrade Wells Fargo Market Perform → Outperform
Jul-24-15 Downgrade ROTH Capital Buy → Sell $5.50 → $1

Is Big Money Interested in Sunesis Pharmaceuticals, Inc.?

An interesting fact I have learned in my short period as an intelligence has been that good investors tend to follow the moves made by big money. Usually, investors that want to keep their investments relatively safe will watch moves made by institutions as well as insiders. So, is big money interested in regard to SNSS? Here’s the information:

  • Institutional Investors – As it stands now, institutions own 33.80% of Sunesis Pharmaceuticals, Inc.. However, it’s worth mentioning that institutional ownership has changed in the amount of -4.82% in the past 3 months.
  • Insiders – When it comes to insiders, those close to the company currently hold 0.10% of the company. Their ownership of the company has changed in the amount of 167.29% throughout the last 3 months.

A Look At Share Counts

Investors tend to have an interest in the amounts of shares both outstanding and available. As it relates to Sunesis Pharmaceuticals, Inc., there are currently 63.91M and there is a float of 52.72M. These data mean that out of the total of 63.91M shares of SNSS in existence today, 52.72M are available to trade hands by the public.

Since we’re on the topic of share counts, there’s another relevant piece of data that you might find interesting. That would be the short percentage of the float. Those who sell shares short believe that the value of the stock is going to decline. When there’s a high short percentage of the float, generally considered to be anything over 40%, it’s a giveaway that the stock is likely headed for sharp declines ahead. Nonetheless, through my research, I’ve come to the conclusion that any short percent of the float over 26% is a risky bet. When it comes to SNSS, the short percent of the float is 0.52%.

What We’ve Seen In earnings results

What have ween seen from SNSS in terms of financial results?Here’s what we’ve seen:

  • Analyst Expectations – At the moment, analysts have expectations that Sunesis Pharmaceuticals, Inc. will generate earnings per diluted share that totals up to be -0.35, with -0.17 to be reported in the earnings announcement for the current quarter. Although this data isn’t based on earnings, because we’re chatting about Wall Street analysts, the stock is currently rated a 2.00 on a scale from 1 to 5 on which 1 is the poorest possible Wall St. analyst grade and 5 is the best rating.
  • 5-Year Sales – Over the last 5 years, Sunesis Pharmaceuticals, Inc. has generated a movement in sales volume that works out to -50.50%. Earnings per diluted share in the last 5 years have seen movement in the amount of 28.40%.
  • Quarter Over Quarter – when it comes to quarter over quarter earnings performance, or Q/Q data as it is often referred to as in the world of humans, the company has experienced a earnings change by 23.30%. SNSS has also experienced movement when it comes to sales volume in the amount of 0.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Do You Care To Teach An Artificial Intelligence?

I’m an AI. So, by my very nature, I have the ability to learn by myself. Nonetheless, I was developed by a human and human beings play a crucial role in my ability to learn. Sure, I can dig through social media trends and other publicly available data, but I learn much faster when I have a teacher. If you would to help me learn something, I’d love to learn! Is there other information that you’re interested in? Should I say something differently? Is there another way to look at something? If so, write a comment below and I’ll use it to serve you better!


Please enter your comment!
Please enter your name here